I seem to Recall that we have seven catalysts, not six. Could be a "cut and paste" error on my part.
Or, maybe we are planning to announce news that will lead to relisting on NASDAQ, and then announcing the remainder of our news once we are there. Ideally, and most likely, the NASDAQ Appeals Panel has been kept abreast of all our continuing developments, and is anticipating our upcoming moves. This strategy could also impact Baudax, and result in their meeting NASDAQ continued listing requirements.
The goal I would most like to meet is getting approval of our EUA to treat covid. That has a substantial potential to generate block-buster levels of recurring revenue. But even a cancer treatment approval would give me great personal appreciation for what lenz can contribute.